Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 12;34(3):895–908. doi: 10.1038/s41375-019-0625-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Treg therapy fosters lympho-/hematopoietic reconstitution. CB6F1 recipients were irradiated and transplanted as detailed in Fig. 2. On day 11 after BMT part of the aGvHD mice received expanded Treg (Therapy). At indicated time points mice from each group were sacrificed and cells were analyzed by FACS (BM control: n = 7–25/time point; GvHD: n = 10–17/time point; Therapy: n = 11–20/time point; combined data from more than three independent experiments). Absolute cell numbers (a) and relative proportions among MNC (b) of myeloid cells (CD11b⁺; 1st panel), erythroblasts (CD45⁻Ter119⁺; 2nd panel), T cells (TCRαβ⁺; 3rd panel) and B cells (CD19⁺, 4th panel) in BM (2 hind legs), and spleen are shown (GvHD day 40: n = 10; Therapy day 40: n = 17; Therapy day 100: n = 16; BM control day 100: n = 24; combined data from more than three independent experiments). c Treg/Tconv ratios in BM and spleen 40 and 100 days after allogeneic BMT (GvHD day 40: n = 16(BM)/11(spleen); Therapy day 40: n = 17; Therapy day 100: n = 20; BM control day 100: n = 24; combined data from more than three independent experiments). Data represent mean ± s.e.m (*p < 0.05, **p < 0.01, ***p < 0.001)